Every PMCPA ruling since 2005 — searchable and filterable by company, clause, and ABPI Code version.
Case Library Membership
Search free — but unlock advanced filters to find every case involving a specific company or clause.
Already a member? Sign in →
Case Library Membership
inc. VAT
inc. VAT · cancel any time
Secure payment via Stripe
Need access for your team?
Company licences available for compliance teams, medical affairs, and training programmes.
Get a team quote →1,930 cases found
A freelance medical writer challenged Ferinject materials used at a renal meeting. The Panel found misleading dosing presentation and misleading CosmoFer comparisons,…
A GP challenged Pfizer’s Toviaz ads comparing fesoterodine 8mg with tolterodine ER 4mg. The PMCPA ruled the comparative claims misleading and unsubstantiated,…
A primary care trust chief pharmacist complained that a representative and materials implied the REACH registry supported Plavix use. The Panel ruled…
A Gardasil press release and related PR emails after the UK HPV tender were ruled misleading and exaggerated, including superiority and “vaccine…
AstraZeneca challenged Trinity-Chiesi’s Fostair cost comparison chart as incomplete and misleading versus Symbicort and Seretide. The Panel found the chart acceptable in…
A freelance medical writer challenged Ferinject materials used at a renal meeting. The Panel ruled claims about dosing and infusion-time comparisons misleading,…
A GP challenged Pfizer’s Toviaz ads comparing fesoterodine 8mg with tolterodine ER. The PMCPA found the comparative claims misleading and unsubstantiated, and…
Complaint about Lantus promotional materials. Panel ruled multiple presentations of comparative dosing/weight data were misleading due to context and incomplete disclosure, breaching…
A pharmacist challenged an Actonel leavepiece citing NICE July 2008. The Panel found the title and quotations misleading, including an unbalanced risedronate…
A letter about the UK HPV vaccine tender was ruled promotional for Gardasil, lacked prescribing information and adverse event reporting guidance, and…
A leavepiece for Acomplia was ruled misleading for implying broader NICE approval than guidance allowed, altering the emphasis of NICE wording on…
Anonymous complainants alleged inappropriate hospitality at a psychiatrists’ meeting sponsored by Bristol-Myers Squibb and Otsuka. The Panel found the meeting’s purpose was…
Roche and Chugai voluntarily admitted a UK media release about unlicensed tocilizumab could be factually incorrect when read alone. The Panel found…
Wyeth challenged Roche/Chugai media claims about unlicensed tocilizumab. The Panel ruled several claims misleading, unsubstantiated and exaggerated, and one statement disparaging anti‑TNF…
A competitor complaint upheld that a Calceos leavepiece misleadingly implied taste-driven preference, long-term adherence and fracture-risk benefits, and used references that did…
Our PMCPA rulings expert has knowledge of over 1,900 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.
